Loading…
← CockpitCompetitor Analysis › 358570.KS GI Innovation, Inc.Open in the cockpit ↗

GI Innovation, Inc.358570.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology
Momentum weak 38
Mkt cap
$339M
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$1.84M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-65.7 pp
WACC 6.5%
Hurdle
n/a
no reverse DCF
Close · KRW₩7,030
1D+0.4%
1W-6.8%
1M-14.3%
3M-20.3%
6M-47.3%
YTD-60.1%
1Y-55.4%
ATR %8.9%
52w lowhigh66.4% off high

What GI Innovation does

Employees: 82

GI Innovation at a glance

Size GI Innovation (358570.KS) is a South Korea Health Care company (Biotechnology) with a market value of $339M, the 444th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩7,030 on 18 Nov 2026.

Performance Over six months the shares fell 47.3%, against -24.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 1,526.8% over the last twelve months (peer median +4.2%); the operating margin is -918.1% (peer median -173.2%).

Valuation It trades at 78.5× enterprise value to sales against a peer median of 5.4× (5th most expensive of 16).

Capital Return on invested capital runs 65.7 points below its cost of capital (6.5% WACC).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 70358570.KS 55
Six months, rebased to 100: GI Innovation against the median of its 20 peers (local-currency closes).

GI Innovation financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩5.50B₩5.84B₩24.3M₩5.32B₩3.50B
Revenue growth—+23,943%-100%+52%—
Gross profit₩3.48B₩2.85B-₩3.08B₩1.99B₩343M
EBITDA-₩48.5B-₩38.7B-₩45.5B-₩52.3B-₩67.2B
Net income-₩44.6B-₩35.1B-₩58.8B-₩55.5B-₩79.8B
Free cash flow-₩50.8B-₩39.7B-₩43.5B-₩41.7B-₩65.5B
Capital expenditure₩7.97B₩7.54B₩24.7M₩579M₩2.97B
Total debt₩1.75B₩5.03B₩12.0B₩3.72B₩4.27B

Quarterly statements and history in the cockpit →

GI Innovation competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-80%-60%-40%-20%0%-25%0%+25%LRMRLYEL38800869002105CCCCCRMD69457630CTNMPROK476060NAUT4894PRTCXFORGLSI358570.KS6-month return →1-month return →
Up and to the right = strong over both horizons. GI Innovation is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×LYEL38800869007630PROK4760604894358570.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GI Innovation is the large dot.

GI Innovation competitors and peer comparison

How GI Innovation compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GI Innovation against its 20 peers (data as of 18 Nov 2026)
Measure358570.KSPeer medianRank in peer set
1-month return-14.3%-2.5%7th lowest of 20
6-month return-47.3%-24.7%4th lowest of 20
Distance from 52-week high-66.4%-51.5%4th lowest of 20
Revenue growth (TTM)+1,526.8%+4.2%highest of 14
Operating margin-918.1%-173.2%6th lowest of 16
EV / Sales78.5×5.4×5th most expensive of 16
ROIC minus cost of capital-65.7 pp-39.6 pp6th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a

Questions

Which companies are GI Innovation's closest peers?
The cockpit's peer set: Larimar Therapeutics (LRMR), Lyell Immunopharma (LYEL), Medtide (3880.HK), Aspen Neuroscience (ASPE), Medy-Tox (086900.KS), Laekna (2105.HK), C4 Therapeutics (CCCC), CorMedix (CRMD).
Is GI Innovation expensive compared with its peers?
On ev / sales it trades at 78.5× against a peer median of 5.4×, 5th most expensive of 16 in its peer set.
How has GI Innovation stock performed?
Over six months to 18 Nov 2026 the shares returned -47.3% against -24.7% for the median peer; over one year -55.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.